Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pathologic Complete Response in HER2-positive BC

JAMA Oncol; ePub 2016 Feb 25; Broglio, et al

Pathologic complete response (pCR) in HER2-positive breast cancer is associated with substantially longer times to recurrence and death. This according to a meta-analysis of 36 studies and 5,768 patients with HER2-positive breast cancer and event-free survival (EFS) by pCR status. Researchers found:

• Overall, the improvement in EFS for pCR vs non-pCR was substantial (HR, 0.37).

• This association was greater for patients with hormone receptor-negative disease (HR, 0.29) than hormone receptor-positive disease (HR, 0.52).

• In randomized clinical trials, the R2 correlations between odds ratios for pCR and HRs were 0.63 for EFS and 0.29 for overall survival (OS).

• Predicted HRs for EFS for RCTs were concordant with observed HRs.

Citation: Broglio KR, Quintana M, Foster M, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: A meta-analysis. [Published online ahead of print February 25, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2015.6113